



CURRICULUM VITAE (CVA)

AVISO IMPORTANTE – El Curriculum Vitae no podrá exceder de 4 páginas. Para rellenar correctamente este documento, lea detenidamente las instrucciones disponibles en la web de la convocatoria.

IMPORTANT – The Curriculum Vitae cannot exceed 4 pages. Instructions to fill this document are available in the website

Fecha del CVA	09/12/2021
----------------------	------------

Parte A. DATOS PERSONALES

Nombre	Jose Antonio		
Apellidos	López Moreno		
Sexo (*)	Male	Fecha de nacimiento	12/05/1971
DNI, NIE, pasaporte	XXXXXXXXXX		
Dirección email	jalopezm@ucm.es	URL Web	www.mideloy.com
Open Researcher and Contributor ID (ORCID) (*)	0000-0003-3552-6101		

* datos obligatorios

A.1. Situación profesional actual

Puesto	Profesor Titular		
Fecha inicio	01/06/2018		
Organismo/ Institución	Complutense University of Madrid		
Departamento/ Centro	Department of Psychobiology and Methodology in Behavioral Sciences.		
País	Spain	Teléfono	677701567
Palabras clave	Psychopharmacology, Alcohol, Genetics, Microbiota, Lateral Flow		

A.2. Situación profesional anterior (incluye interrupciones en la carrera investigadora, de acuerdo con el Art. 14. 2.b) de la convocatoria, indicar meses totales)

Periodo	Puesto/ Institución / País / Motivo interrupción
2011 - 2018	Profesor Contratado Doctor/Universidad Complutense de Madrid/España
2007 - 2011	Profesor Ayudante Doctor/Universidad Complutense de Madrid/España
2005 - 2007	Profesor Ayudante/Universidad Complutense de Madrid/España
2004 – 2005	Profesor Titular /Colegio Universitario Cardenal Cisneros (UCM)/España
2002 – 2004	Beca Formación de Profesorado Universitario (FPU)/ (UCM)/España
2001 – 2001	Beca Investigación / Instituto de Salud Carlos III/España
2000 – 2001	Beca de Colaboración (Investigación)/ (UCM)/España

A.3. Formación Académica

Grado/Master/Tesis	Universidad/Pais	Año
PhD in Medicine	Complutense University of Madrid	Currently
PhD in Neuroscience	Complutense University of Madrid	2005
Degree in Psychology	Complutense University of Madrid	2001

Parte B. RESUMEN DEL CV (máx. 5000 caracteres, incluyendo espacios):

I am the author of **51 scientific publications**, all international and peer reviewed. **55% in the first quartile (Q1)**. Author also of three chapters of international books. Having as axis addiction studies, and especially alcohol, I have been incorporating lines of research progressively. At first it was the neurobiology of the endocannabinoid system. Subsequently, gene expression studies were added, then genetic association studies in humans, then epigenetic studies in animal and human models, and more recently studies on the gut microbiota and the gut-brain axis. As a result of all these works, we have been able to advance in the knowledge of pharmacological treatments in alcohol addiction



and / or its prevention. With the COVID-19 pandemic, we introduced our experience as a technology-based company for the development of rapid lateral flow tests, for detection of antibodies/antigens. Most of my publications are in collaborations with other national and international research groups (see section C2). As main researcher I have directed multiple competitive international, national and/or regional projects (see section C3). I have also obtained various contracts (Art. 83) with public and private institutions (see section C4). **The total amount of funding obtained as Principal Investigator in the last 10 years amounts to 1.567.490,3 €*** *Other grants received, but not shown in the CV, have not been added.

We have worked for several years in addiction prevention programs in schools in the Community of Madrid, reaching more than 30,000 students. All this has been articulated through Articles 83. In 2015 we created the Technological Base Company of the Complutense University, Mideloy SL, specialized in the development of rapid lateral flow tests. During the pandemic we have collaborated with the Arganda del Rey City Council in the evaluation of COVID-19 antibodies of more than 20,000 people with rapid tests. We were among the first to commercialize antibody tests - April 2020- in Spain.

Regarding my training activities, I have directed five theses already defended (two of them with an extraordinary prize) and another two that will be defended soon. I have directed 31 Final Master's Projects. Currently, I have three "Sexenios de Investigación" (six-year research period reviewed) and one "Sexenio de Transferencia", that revalidate my work as a researcher and the transfer of my research to the society repeatedly.

Parte C. LISTADO DE APORTACIONES MÁS RELEVANTES (últimos 10 años)

C.1. Publicaciones más importantes en libros y revistas con "peer review" y conferencias

1: Calleja-Conde J, Echeverry-Alzate V, Bühler KM,...**López-Moreno JA (AC) (9/9)**. The Immune System through the Lens of Alcohol Intake and Gut Microbiota. Int JMol Sci. 2021 Jul 13;22(14):7485. doi: 10.3390/ijms22147485. PMID: 34299105;PMCID: PMC8303153. IF (2020): **5.9 (Q1)** Nº OF CITATIONS (03/12/2021): **0**

2: Morales-Garcia JA, Calleja-Conde J, **Lopez-Moreno JA**, Alonso-Gil S, Sanz- SanCristobal M, Riba J, Perez-Castillo A (AC) **(3/7)**. N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo. Transl Psychiatry. 2020 Sep 28;10(1):331. doi: 10.1038/s41398-020-01011-0. PMID: 32989216; PMCID: PMC7522265. IF (2020): **6.2 (Q1)** Nº OF CITATIONS (03/12/2021): **10**

3: Alen F, Decara J, Brunori G,... Rodríguez de Fonseca F (AC) **(6/14)**. PPAR α /CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models. BiochemPharmacol. 2018 Nov;157:235-243. doi:10.1016/j.bcp.2018.09.008. Epub 2018 Sep 6. PMID: 30195735. IF (2018): **4,825 (Q1)** Nº OF CITATIONS (03/12/2021): **5**

4: Giné E, Echeverry-Alzate V, **Lopez-Moreno JA**, Rodriguez de Fonseca F, Perez-Castillo A, Santos A (AC) **(3/6)**. The CB1 receptor is required for the establishment of the hyperlocomotor phenotype in developmentally-induced hypothyroidism in mice. Neuropharmacology. 2017 Apr;116:132-141. doi: 10.1016/j.neuropharm.2016.12.018. Epub 2016 Dec 23. PMID: 28017790. IF (2016): **4,249 (Q1)** Nº OF CITATIONS (03/12/2021): **3**

5: Celorrio M, Fernández-Suárez D, Rojo-Bustamante,..., Aymerich MS (AC) **(7/11)**. Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease. Brain Behav Immun. 2016 Oct;57:94-105. doi: 10.1016/j.bbi.2016.06.010. Epub 2016 Jun 16. PMID: 27318096. IF (2016): **5,964 (Q1)** Nº OF CITATIONS (03/12/2021): **36**

6: Calleja-Conde J, Echeverry-Alzate V, Giné E, Bühler KM, Nadal R, Maldonado R, Rodríguez de Fonseca F, Gual A, **López-Moreno JA (AC) (8/8)**. Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood. Br J Pharmacol. 2016 Aug;173(16):2490-505. doi: 10.1111/bph.13526. Epub 2016 Jul 18. PMID: 27238566; PMCID: PMC4959953. IF (2016): **5,491 (Q1)** Nº OF CITATIONS (03/12/2021): **11**

7: **López-Moreno JA (AC)**, Marcos M, Calleja-Conde J,...,Giné E **(1/13)**. Histone Deacetylase Gene Expression Following Binge Alcohol Consumption in Rats and Humans. Alcohol Clin Exp Res. 2015 Oct;39(10):1939-50. doi: 10.1111/acer.12850. Epub 2015 Sep 13. PMID: 26365275. IF (2015): **2,829 (Q2)** Nº OF CITATIONS (03/12/2021): **23**



8: Bühler KM, Giné E, Echeverry-Alzate V, Calleja-Conde J, de Fonseca FR, **López- Moreno JA (AC) (6/6)**. Common single nucleotide variants underlying drug addiction: more than a decade of research. *Addict Biol.* 2015 Sep;20(5):845-71. doi: 10.1111/adb.12204. Epub 2015 Jan 21. PMID: 25603899. IF (2015): **4,547 (Q1)** Nº OF CITATIONS (03/12/2021): **66**

9: Echeverry-Alzate V, Giné E, Bühler KM,...,**López-Moreno JA (AC) (9/9)**. Effects of topiramate on ethanol-cocaine interactions and DNA methyltransferase gene expression in the rat prefrontal cortex. *Br J Pharmacol.* 2014 Jun;171(12):3023-36. doi: 10.1111/bph.12636. PMID: 24527678; PMCID: PMC4055203. IF (2015): **4,842 (Q1)** Nº OF CITATIONS (03/12/2021): **13**

10: Echeverry-Alzate V, Tuda-Arízcon M, Bühler KM,...,**López-Moreno JA (AC) (10/10)**. Cocaine reversesthe naltrexone-induced reduction in operant ethanol self-administration: theeffects on immediate-early gene expression in the rat prefrontal cortex. *Neuropharmacology.* 2012 Nov;63(6):927-35. doi: 10.1016/j.neuropharm.2012.06.010. Epub 2012 Jun 28. PMID: 22749946. IF (2015): **4,11 (Q2)** Nº OF CITATIONS (03/12/2021): **11**

C.2. Congresos

Congress: Spanish society for microbiota, probiotics and prebiotics

Title: Relationship between intestinal microbiota and alcohol consumption.

Authors: **López-Moreno J.A.**, Rincón-Pérez I, Bühler KM, Calleja-Conde J, Segovia L, Giné E, Albert J, Hinojosa JA, Rodríguez de Fonseca F, J Echeverry-Alzate V

Modality: Oral Com. - Award for best oral communication in the field of preclinical research

Date and location: 12-14^º of february 2020 (Granada)

Congress: European Society for Biomedical Research on Alcoholism Congress

Title: Translational studies in alcohol-induced changes in gut microbiota

Authors: López-Moreno J.A., Rincón-Pérez I, Echeverry-Alzate V, Bühler K, Calleja-Conde J, Segovia L, Giné E, Rodríguez de Fonseca F1, Albert J, Hinojosa J.A.

Modality: Oral Communication

Date and location: 21-24^º of september 2019 (Lille/Francia)

Organizer of the 19th Annual Genes, Brain and Behavior Meeting (International Behavioral and Neural Genetics Society, IBANGS) held in Madrid from 15th to 18th of May, 2017 (Faculty of Medicine, Complutense University Madrid)

C.3. Proyectos o líneas de investigación en los que ha participado

1: **Project reference:** ANTICIPA-CM

Title: Anticipation and Prevention of COVID-19 in the Community of Madrid

Financing entity: Ministry of Education, Com. of Madrid and European Regional Development Fund.

Period: 2021-2022 / **Principal Investigator:** Jose Antonio López Moreno, UCM

Funding: 8.489.999,91 € (**118.895,2 €** al grupo de investigación)

2: **Project reference:** ANT-UNIV-COVID19

Title: Analysis of COVID-19 Antibodies in the Spanish University System.

Financing entity: CRUE-Banco Santander

Period: 2020-2021 / **Principal Investigator:** Jose Antonio López Moreno, UCM

Funding: **90.000 €**

3: **Project reference:** 2018-050

Title: Alcohol and Gut Microbiota Considering Gender / Sex Differences

Financing entity: National Plan on Drugs, Ministry of Health

Period: 2019-2021 / **Principal Investigator:** Jose Antonio López Moreno, UCM

Funding: **72.000 €**

4: **Project reference:** RD16/0017/0008

Title: Funding for stable cooperative research structures in the area of biomedicine and health (networks of cooperative research - health-Network of Addictive Disorders – ISCIII)

Financing entity: UCM

Period: 2017-2021 / **Principal Investigator:** Jose Antonio López Moreno, UCM

Funding: **89.034€**



<p>5: Project reference: RD12/0028/0015 Title: Funding for stable cooperative research structures in the area of biomedicine and health (networks of cooperative research - health-Network of Addictive Disorders – ISCIII) Financing entity: UCM Period: 2013-2106 / Principal Investigator: <u>Jose Antonio López Moreno, UCM</u> Funding: 94.300€</p>
<p>6: Project reference: SAF2011-26818 Title: Integración del sistema endocannabinoide y la proteína alfa-sinucleína: caracterización farmacológica de la adicción al alcohol y a la cocaína. Financing entity: Ministry of Science and Innovation Period: 2012-2014 / Principal Investigator: <u>Jose Antonio López Moreno, UCM</u> Funding: 108.900€</p>
<p>7: Project reference: EA1221 Title: Brain and plasma epigenetic marker for alcohol addiction and its cognitive deficits Financing entity: The European Foundation of Alcohol Research Period: 2012-2013 / Principal Investigator: <u>Jose Antonio López Moreno, UCM</u> Funding: 50.000€</p>

C.4. Participación en actividades de transferencia de tecnología/conocimiento y explotación de resultados

<p>1: Contract reference: 472-2020 Contrato-Art.83 Title: Serological study of IgM/IgG prevalence against SARS-CoV-2 in Arganda del Rey Financing entity: Arganda del Rey City Council Period: 05/01/2021 – 31/07/2021 / Principal Investigator: <u>Jose Antonio López Moreno, UCM</u> Funding: 494.479,7 €</p>
<p>2: Contract reference: 355/2019. Contrato-Art.83 Title: Determinants of Alcohol Consumption in Minors Financing entity: Alcohol and Society Foundation Period: 10/07/2019 – 10/07/2020 / Principal Investigator: <u>Jose Antonio López Moreno, UCM</u> Funding: 45.980 €</p>
<p>3: Contract reference: FCT18-13622/FCT17-12187 Title: National evaluation of scientific culture in compulsory secondary education Financing entity: Spanish Foundation for Science and Technology (FECYT) Period: 01/08/2018 – 30/06/2020 / Principal Investigator: <u>Jose Antonio López Moreno, UCM</u> Funding: 44.000 €</p>
<p>4: Contract reference: 2013/2016. Contrato-Art.83 Title: Evaluation of Drug Dependence Prevention Programs in public schools in Madrid Financing entity: Madrid Anti-Drug Agency / Ministry of Health Period: 01/01/2013 – 31/12/2016 / Principal Investigator: <u>Jose Antonio López Moreno, UCM</u> Funding: 239.934,4 €</p>
<p>5: Contract reference: 2011/2012. Contrato-Art.83 Title: Evaluation of Drug Dependence Prevention Programs in public schools in Madrid Financing entity: Madrid Anti-Drug Agency / Ministry of Health Period: 01/01/2011 – 31/12/2012 / Principal Investigator: <u>Jose Antonio López Moreno, UCM</u> Funding: 119.967 €</p>
<p>Creation of the Technology-based company of the Complutense University of Madrid, MIDELOY SL (https://www.mideloy.com/), specialized in the development of Rapid Diagnostic Tests using lateral flow techniques. Founding members: <u>Jose Antonio López Moreno</u> & Elena Giné Domínguez Creation date: 2015</p>